Background
Recurrence of advanced melanoma after checkpoint therapy is a major risk factor for death, and treatment options are limited. Anti-tumor memory plays a critical role in preventing recurrence, but the identity, location and functional properties of the immune cells required for anti-tumor memory are not understood.
Methods
Using a mouse model that allows tracking tumor-specific CD8+ T cells, immunophenotyping using flow cytometry and single cell analyses with RNA-Seq, CITE-Seq and ATAC-Seq, we isolated and characterized T-cell populations in lymphoid organs after immunotherapy and tested their functional roles in maintaining tumor remission in mice in vivo. We investigated our findings in large human melanoma cohorts at Yale and from other institutions.
Results
Here, we show that an IL-7Rhi tumor-specific CD8+ population with a distinct epigenetic landscape is critical for antitumor memory and can be epigenetically augmented to drive powerful anti-tumor immune responses.This IL-7Rhi memory CD8+ population expresses intrinsic cytotoxic activity, potently upregulates effector genes and cytokines in response to tumor re-challenge and lacks exhaustion markers. The rapid cytotoxic response is enabled by a functionally poised epigenetic landscape, which can be augmented by hypomethylating agents ex vivo. The IL-7Rhi population has superior antitumor efficacy and adoptive transfer confers improved survival and melanoma clearance in 80% of mice. Importantly, greater than 95% of tumor-specific T-cells in lymph nodes after immunotherapy express high levels of IL-7R. This overlap between IL-7Rhi and tumor-specificity allows for enrichment of a potent functional T cell subset without determining neoantigens, which we demonstrate in a melanoma model without a known antigen.Integrating our findings with human melanoma, we identify that IL-7R expression in the TME is an independent prognostic factor of improved survival.
Conclusions
These findings advance our understanding of anti-tumor memory and suggest a novel T cell-based therapy for melanoma using high IL-7R expression to enrich for a population with superior anti-tumor activity that can be augmented by hypomethylating agents.